part1:EA-EMC-T
PreclinicalSmall molecule
part1:EA-EMC-T is one of 7 small molecule programs targeting Gastrointestinal. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Gastrointestinal
#DrugCompanyPhaseTrials
1Movantik
AAveritas Pharma, Inc.
Phase 3
Cytalux
OOn Target Laboratories, LLC
Phase 3
Octreotide
Johnson & JohnsonPreclinical
Mosapride Citrate
IlDong Pharmaceutical Co LtdPreclinical
part1:EA-EMC-T
SSun Yat-sen University
Preclinical
Buscopan
Boehringer IngelheimPreclinical
Dachengqi Decoction
XXinhua Hospital, Shanghai Jiao Tong University School of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for part1:EA-EMC-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SSun Yat-sen University